​If you or someone you know has a peanut allergy, then here's some news worth celebrating.

​If you or someone you know has a peanut allergy, then here's some news worth celebrating.

One of our clients, Allergy Therapeutics, a UK-based biotechnology company specializing in allergy vaccines, announced the start of the first application of its ‘VLP Peanut’ vaccine candidate in peanut-allergic patients on Monday. The firm said its short-course peanut allergy vaccine was being tested in the phase one ‘PROTECT’ trial.

The first-in-human study is focussed on evaluating the safety and tolerability of VLP Peanut in healthy and peanut-allergic adult subjects, while exploring preliminary proof of efficacy.

"Allergy Therapeutics wholly-owned, subcutaneous, recombinant vaccine candidate incorporates novel virus-like particle (VLP) technology, which enhances the body's immune response by making the peanut allergen resemble an inactive virus,” the company explained in its statement.

VLP Peanut is a novel vaccine candidate that uses virus-like particles to deliver the peanut allergen to the body. This technology is designed to enhance the body's immune response to the allergen, which may lead to a reduction in the severity of allergic reactions.

The Phase I PROTECT trial is a first-in-human study that will evaluate the safety and tolerability of VLP Peanut in healthy and peanut-allergic adult subjects. The trial will also explore preliminary proof of efficacy, which means that it will look at whether the vaccine is able to reduce the severity of allergic reactions to peanuts.

If you or someone you know has a peanut allergy, this news is worth celebrating! VLP Peanut has the potential to revolutionize the way we treat peanut allergies, and we're excited to see the results of this trial.